Skip to Content

PolyMedix Announces Presentation of Four Abstracts at ECCMID 2011 Meeting

RADNOR, Pa.--(BUSINESS WIRE)--May 5, 2011 - PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, today announced the acceptance of four presentations on the Company's lead antibiotic drug candidate, PMX-30063, at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). ECCMID attracts more than ten thousand experts each year, covering key topics of infectious disease including diagnosis, prevention, pathogenesis, treatment, and antibiotic resistance. The meeting will take place in Milan, Italy from May 7-10, 2011.

The following abstracts will be presented:

New Antimicrobial Drugs in the Pipeline


Oral Presentation


Abstract Title: Investigation of Potential Mechanisms Underlying Transient Parasthesia associated with PMX-30063 Administration in Human Subjects


Presentation Date/Time: Saturday, May 7, 2011, 18:18 – 18:30


Presenter: B. Korczak (Radnor, PA)


Abstract Control Number: O 97


New Targets for New Antimicrobials


Poster Session


Abstract Title: In Vitro Activity Profile of PMX-30063 Against Recent Clinical Isolates of Gram-positive and Gram-negative Pathogens


Presentation Date/Time: Sunday, May 8, 2011, 13:30 – 14:30


Presenter: B. Korczak (Radnor, PA)


Abstract Control Number: P 1168


New Antimicrobials: Preclinical and Clinical Studies


Poster Session


Abstract Title: A Phase 1 Trial to Evaluate the Tolerability, Safety and Pharmacokinetics of Multi-dose Intravenous Regiments of PMX-30063


Presentation Date/Time: Monday, May 9, 2011, 12:30 – 13:30


Presenter: B. Korczak (Radnor, PA)


Abstract Control Number: P 1515


New Antimicrobials: Preclinical and Clinical Studies


Poster Session


Abstract Title: Understanding Neuronal Effects in Multi Dose – Phase 1 Clinical Study


Presentation Date/Time: Monday, May 9, 2011, 12:30 - 13:30


Presenter: B. Korczak (Radnor, PA)


Abstract Control Number: P 1514


About PMX-30063

PolyMedix's novel antibiotic compound, PMX-30063, is a small-molecule designed to mimic the activity of human host-defense proteins (HDPs), the body's natural defense against bacterial infections. HDPs kill bacteria by directly targeting bacterial membranes and disrupting them. Widespread resistance to this unique mechanism of action has not developed despite millions of years of evolution. With PMX-30063 designed to mimic HDPs, we believe that resistance is also unlikely to evolve to this novel antibiotic, making PMX-30063 one potential solution to the growing problem of bacterial resistance. PMX-30063 is currently in a Phase 2 clinical trial to treat patients with Acute Bacterial Skin and Skin Structure Infections caused by Staph bacteria.

About PolyMedix, Inc.

PolyMedix is a publicly traded biotechnology company focused on the development of novel drugs for the treatment of serious infectious diseases and acute cardiovascular disorders. PolyMedix uses a rational drug design approach to create non-peptide, small-molecule drug candidates. PolyMedix's lead antibiotic compound, PMX-30063, is currently in a Phase 2 clinical trial for treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by Staph, including MRSA. PMX-30063 is a small-molecule that mimics the mechanism of action of human host defense proteins, a mechanism that is distinct from currently approved antibiotic drugs and is intended to make bacterial resistance unlikely to develop. PolyMedix's lead heptagonist compound, PMX-60056, is in a Phase 2 clinical trial in patients undergoing PCI procedures. PMX-60056 is designed to reverse the anticoagulant activity of both heparin and low molecular weight heparins (LMWH). PolyMedix believes that PMX-60056 could potentially be a safer and easier to use anticoagulant reversing agent, with broader activity, than the currently approved therapy for reversing heparin and LMWH. In addition to its small molecule therapeutics, PolyMedix has polymeric formulations with the same mechanism of action as PMX-30063, PolyCides®. PolyCides are intended for use in antimicrobial biomaterials applications as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces.

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause PolyMedix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. PolyMedix has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are PolyMedix's need for, and the availability of, substantial capital in the future to fund its operations and research and development, and the fact that PolyMedix's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in PolyMedix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. PolyMedix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

Posted: May 2011